一名接受厄洛替尼治疗的肺癌患者的银屑病病情得到改善。 - Suppr

Suppr

超能文献

Improvement of psoriasis in a lung cancer patient treated with erlotinib.

作者信息

Giroux Leprieur Etienne, Friard Sylvie, Couderc Louis-Jean

出版信息

Eur J Dermatol. 2010 Mar-Apr;20(2):243-4. doi: 10.1684/ejd.2010.0882. Epub 2010 Feb 2.

DOI:10.1684/ejd.2010.0882

PMID:20123646

Abstract

摘要

相似文献

Improvement of psoriasis in a lung cancer patient treated with erlotinib.

Eur J Dermatol. 2010 Mar-Apr;20(2):243-4. doi: 10.1684/ejd.2010.0882. Epub 2010 Feb 2.

Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis?

Br J Dermatol. 2006 Jul;155(1):213-4. doi: 10.1111/j.1365-2133.2006.07299.x.

Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.

J Thorac Oncol. 2014 May;9(5):e37-9. doi: 10.1097/JTO.0000000000000097.

A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.

Cancer Chemother Pharmacol. 2012 May;69(5):1241-6. doi: 10.1007/s00280-012-1831-0. Epub 2012 Jan 26.

Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy?

Dermatology. 2012;225(2):179-82. doi: 10.1159/000342786. Epub 2012 Oct 20.

Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.

Anticancer Res. 2010 Feb;30(2):557-63.

Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.

Prescrire Int. 2011 Oct;20(120):234.

High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.

J Thorac Oncol. 2011 Mar;6(3):653-4. doi: 10.1097/JTO.0b013e3181d899bb.

Wood-smoke exposure (WSE) as a predictor of response and survival in erlotinib-treated non-small cell lung cancer (NSCLC) patients.

J Thorac Oncol. 2009 Jan;4(1):142-3. doi: 10.1097/JTO.0b013e3181915fb6.

Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy.

JAMA Ophthalmol. 2014 Sep;132(9):1150-2. doi: 10.1001/jamaophthalmol.2014.1088.

引用本文的文献

Impaired wound healing in Parkinson's disease: a hypothesis on altered epidermal growth factor (EGF) and N-methyl-D-aspartate (NMDA) signaling in keratinocytes.

Mol Med. 2025 May 22;31(1):201. doi: 10.1186/s10020-025-01247-w.

Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents.

Dermatol Ther (Heidelb). 2024 Jul;14(7):1755-1766. doi: 10.1007/s13555-024-01198-w. Epub 2024 Jun 22.

Recent advances on the roles of epidermal growth factor receptor in psoriasis.

Am J Transl Res. 2019 Feb 15;11(2):520-528. eCollection 2019.

Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis.

Int J Biomed Sci. 2013 Sep;9(3):112-22.

Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases.

Oncologist. 2013;18(1):e3-5. doi: 10.1634/theoncologist.2012-0219.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验